Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refrac...
Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
21 Sep 2021
New MM patients with high levels of circulating tumour cells distinguished by in...
Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands
New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )
21 Sep 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
Disparities in myeloma: Closing the gap
Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Disparities in myeloma: Closing the gap ( Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
19 Sep 2021
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL am...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
19 Sep 2021
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...
Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )
18 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )
14 Sep 2021
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021